Search Results for "corticosteroids, injectable"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for corticosteroids, injectable. Results 11 to 20 of 46 total matches.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
use of a low-dose inhaled corticosteroid (ICS)
plus a SABA or a low-dose ICS in combination ...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92 doi:10.58347/tml.2024.1716a | Show Introduction Hide Introduction
Belimumab (Benlysta) for Lupus Nephritis (online only)
The Medical Letter on Drugs and Therapeutics • Sep 23, 2021 (Issue 1634)
(cyclophosphamide
or mycophenolate mofetil; addition of a corticosteroid
was up to the investigator) and were ...
The B-lymphocyte stimulator (BLyS)-specific inhibitor
belimumab (Benlysta – GSK), which was approved
earlier for treatment of active, autoantibody-positive,
nonrenal, systemic lupus erythematosus (SLE), has
now been approved for use in addition to standard
therapy for treatment of active lupus nephritis in
adults. Belimumab is the first drug to be approved in
the US for treatment of both SLE and lupus nephritis.
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
of severe
refractory atopic dermatitis. Oral corticosteroids
are FDA-approved for treatment of atopic ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
intra-articular injection
Pregnancy: low-dose corticosteroids are
generally considered safe for short ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction
Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
suspension formulation of
the corticosteroid budesonide, has been approved
by the FDA for treatment ...
Eohilia (Takeda), an oral suspension formulation of
the corticosteroid budesonide, has been approved
by the FDA for treatment of eosinophilic esophagitis
(EoE) in patients ≥11 years old. It is the first oral
drug to be approved in the US for this indication. The
subcutaneously injected interleukin (IL)-4 receptor
antagonist dupilumab (Dupixent) is approved
for treatment of EoE in patients ≥1 year old who
weigh ≥15 kg.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):93-5 doi:10.58347/tml.2024.1704c | Show Introduction Hide Introduction
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
$366.505
1761.005
1693.605
224.10
1161.80
Oral Corticosteroids
Prednisone – generic
delayed-release ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
Risankizumab (Skyrizi) — An IL-23 Antagonist for Crohn's Disease
The injectable interleukin (IL ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzaa (Skyrizi – Abbvie) has been
approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults.
Risankizumab was approved earlier for treatment of
plaque psoriasis and psoriatic arthritis.
Guselkumab (Tremfya) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
for use when TNF inhibitors are ineffective or not
tolerated.4-7
Corticosteroids can be used ...
The interleukin (IL)-23 antagonist guselkumab
(Tremfya – Janssen Biotech) has now been approved
by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was
approved earlier for treatment of plaque psoriasis
and psoriatic arthritis. Guselkumab is the third IL-23
antagonist to be approved in the US for treatment of
UC; risankizumab (Skyrizi) and mirikizumab (Omvoh)
were approved earlier.
Med Lett Drugs Ther. 2025 Mar 17;67(1724):46-8 doi:10.58347/tml.2025.1724d | Show Introduction Hide Introduction
COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
that adults with COVID-19 who require IMV or
ECMO receive the corticosteroid dexamethasone
and either ...
The investigational anti-complement component 5a
(C5a) antibody vilobelimab (Gohibic – InflaRx) has
been granted an FDA Emergency Use Authorization
(EUA) for IV treatment of hospitalized adults
with COVID-19 beginning within 48 hours after
invasive mechanical ventilation (IMV) or extracorporeal
membrane oxygenation (ECMO) is started.
Vilobelimab is the first anti-C5a antibody to become
available in the US.
Med Lett Drugs Ther. 2023 May 29;65(1677):86-7 doi:10.58347/tml.2023.1677d | Show Introduction Hide Introduction
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
that mimics an
exacerbation of UC can occur with mesalamine.
CORTICOSTEROIDS — Corticosteroids are effective ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction